Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 5/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | ALB | P02768 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | TYMP | P19971 | 2/20 | 0.40 |
| ▸ | TK2 | O00142 | 2/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12658380 | 1.00 | TK1 (0.43) | TK1ALDH1A1ALBLMNAPOLB | |
| SCHEMBL12482719 | 0.89 | TK1 (0.41) | TK1ALDH1A1ALBLMNAPOLB | |
| SCHEMBL27799099 | 0.89 | TK1 (0.41) | TK1ALDH1A1ALBLMNAPOLB | |
| SCHEMBL5954319 | 0.88 | TK1 (0.37) | TK1ALDH1A1ALBLMNAPOLB | |
| SCHEMBL26666707 | 0.87 | PYGM (0.38) | TK1LMNATK2 | |
| SCHEMBL6829243 | 0.86 | PYGM (0.37) | TK1LMNATK2 | |
| SCHEMBL6537910 | 0.86 | LMNA (0.46) | LMNAADRA1ATK2 | |
| SCHEMBL8904559 | 0.85 | TK1 (0.43) | TK1ALDH1A1ALBLMNAPOLB | |
| SCHEMBL29136420 | 0.84 | KMT2A (0.41) | ALDH1A1 | |
| SCHEMBL29087629 | 0.84 | P2RY6 (0.38) | TK1LMNATK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103328655-B | Signal amplifies | SPEEDX PTY LTD. (AU) | 2018-02-09 | — | — | CN | claimed |
| WO-2008109551-A1 | NUCLEIC ACID COMPOUNDS FOR INHIBITING TACSTD1 GENE EXPRESSION AND USES THEREOF | MDRNA, INC. (US) | 2008-09-12 | — | — | WO | claimed |
| WO-2025106738-A1 | SARS-COV-2 IMMUNOGENIC COMPOSITIONS | BioNTech SE (DE) | 2025-05-22 | — | — | WO | disclosed |
| US-20250017970-A1 | Reduced Expression of Sarm1 For Use In Cell Therapy | EMENDOBIO INC. | 2025-01-16 | — | — | US | disclosed |
| WO-2024064607-A9 | BIALLELIC KNOCKOUT OF TET2 | EMENDOBIO INC. (US) | 2024-07-25 | — | — | WO | disclosed |
| EP-4396349-A1 | COMPOSITIONS AND METHODS FOR MODULATING NLRP3 OR NLRP1 EXPRESSION | Molecular Axiom, LLC (US) | 2024-07-10 | — | — | EP | disclosed |
| WO-2024138135-A2 | COMPOSITIONS AND METHODS FOR MODULATING SOS GENE EXPRESSIONS | MOLECULAR AXIOM, LLC (US) | 2024-06-27 | — | — | WO | disclosed |
| US-20240175013-A1 | BIALLELIC KNOCKOUT OF TRAC | EMENDOBIO INC. (US) | 2024-05-30 | — | — | US | disclosed |
| WO-2024054867-A1 | MODIFIED MOLECULAR BEACONS FOR IMPROVED DETECTION SPECIFICITY | BECTON, DICKINSON AND COMPANY (US) | 2024-03-14 | — | — | WO | disclosed |
| EP-4259160-A1 | BIALLELIC KNOCKOUT OF B2M | Emendobio Inc. (US) | 2023-10-18 | — | — | EP | disclosed |
| WO-2023176863-A1 | CHEMICALLY-MODIFIED OLIGONUCLEOTIDE HAVING RNAI ACTIVITY | 第一三共株式会社 | 2023-09-21 | — | — | WO | disclosed |
| WO-2005049832-A2 | FcϜRIIA-SPECIFIC NUCLEIC ACID INTERFERENCE | YALE UNIVERSITY (US) | 2005-06-02 | — | — | WO | disclosed |
| WO-2005049838-A2 | SYK-TARGETED NUCLEIC ACID INTERFERENCE | YALE UNIVERSITY (US) | 2005-06-02 | — | — | WO | disclosed |
| WO-2005035547-A2 | E2F OLIGONUCLEOTIDE DECOY MOLECULES | CORGENTECH, INC. (US) | 2005-04-21 | — | — | WO | disclosed |
| EP-1246833-A4 | IMPROVED SYNTHESIS OF SULFURIZED OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS INC (US) | 2003-04-09 | — | — | EP | disclosed |
| WO-2003016572-A1 | OLIGONUCLEOTIDE THERAPEUTICS FOR TREATING HEPATITIS C VIRUS INFECTIONS | ELI LILLY AND COMPANY (US) | 2003-02-27 | — | — | WO | disclosed |
| EP-1246833-A1 | IMPROVED SYNTHESIS OF SULFURIZED OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS, INC. (US) | 2002-10-09 | — | — | EP | disclosed |
| WO-2001051502-A1 | IMPROVED SYNTHESIS OF SULFURIZED OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS, INC. (US) | 2001-07-19 | — | — | WO | disclosed |
| EP-1053313-A1 | OPTIMIZED ANTISENSE OLIGONUCLEOTIDES COMPLEMENTARY TO DNA METHYLTRANSFERASE SEQUENCES | Methylgene, Inc. (CA) | 2000-11-22 | — | — | EP | disclosed |
| WO-1999040186-A1 | OPTIMIZED ANTISENSE OLIGONUCLEOTIDES COMPLEMENTARY TO DNA METHYLTRANSFERASE SEQUENCES | METHYLGENE, INC. (CA) | 1999-08-12 | — | — | WO | disclosed |